Summary
We present pharmacokinetic data of prolonged, intra-arterial indomethacin treatment (i.e. induction plus maintenance dose) for symptomatic patent ductus arteriosus (sPDA) in 26 ventilated premature infants. sPDA was assessed by two-dimensional and pulsed Doppler echocardiography. Permanent ductal closure occurred in 20 (76%) infants. Plasma levels of indomethacin were 1.18±0.74; 1.8±1.0; 1.51±0.93 and 1.25±0.98 μg/ml (mean±SD) at 12, 24, 48 and 72 h after initial dose administration. All except one patient who responded with ductal closure, showed plasma levels above 0.25 μg/ml throughout the 3 day treatment period and no case of sPDA reopening was noted. Although target concentrations over time were not defined, the data indicate that the maintenance levels measured were within the therapeutic range. A negative correlation was found for plasma drug levels and postnatal age (r=0.52;P<0.01). Volume of drug distribution was 0.23±0.18l/kg, total clearance 0.1±0.11 ml/min and elimination constant 0.06±0.05h−1 (mean±SD). The great variation in pharmacokinetic data reflects the heterogeneity of the population studied with respect to extracellular fluid space, cardiovascular status, serum protein and other parameters.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- sPDA:
-
symptomatic patent ductus arteriosus
References
Brash AR, Hickey DE, Graham ThP, Stahlman MT, Oates JA, Cotton RB (1981) Pharmacokinetics of indomethacin in the neonate: relation of plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med 305:67–72
Friedman CA, Parks BR, Rawson JE, Serwer GA, Anderson PAW (1982) Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure. Dev Pharmacol Ther 4:37–46
Friis-Hansen B (1971) Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth. Pediatrics 47:264–274
Gersony WM (1986) Patent ductus arteriosus in the neonate. Pediatr Clin North Am, The Newborn II, Toxikology II 33:545–560
Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS (1983) Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 102:895–906
Gittenberg-de Groot AC, Ertbruggen I van, Moulaert AJ, Harinck A (1980) The ductus arteriosus in the preterm infant: histologic and clinical observations. J Pediatr 96:88–93
Gomeni R (1984) Pharm, an interactive graphic program for individual and population pharmacokinetic parameter estimation. Comp Biol Med 14:25–34
Harris JP, Merrit A, Alexson ChG, Longfield L, Manning JA (1982) parenteral indomethacin for closure of the patent ductus arteriosus. Am J Dis Child 136:1005–1008
Khoss AE, Ponhold W, Pollak A, Schlemmer M, Weninger M (1985) Abdominal aortic aneurysm in a premature neonate with disseminated candidiasis: ultrasound and angiography. Pediatr Radiol 15:420–421
Leonhardt A, Isken V, Kühl PG, Seyberth HW (1987) Prolonged indomethacin treatment in preterm infants with symptomatic patent ductus arteriosus: efficacy, drug level monitoring, and patient selection. Eur J Pediatr 146:140–144
Mellander M, Leheup B, Lindstrom DP, Palme Ch, Grahem ThP, Stahlman MT, Cotton RB (1984) Recurrence of symptomatic patent ductus arteriosus in extremely premature infants, treated with indomethacin. J Pediatr 105:138–143
Pollak A, Weninger M, Salzer HR, Salzer-Muhar U, Levin S, Mascher H (1986) Liquid-chromatographic determination of plasma indomethacin in premature infants with patent ductus arteriosus. IRCS Med Sci 14:813–814
Rhodes PG, Ferguson MG, Reddy NS, Joransen JA, Gibson J (1988) Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus. Eur J Pediatr 147:481–484
Salzer HR, Pollak A, Weninger M, Salzer-Muhar U (1987) Sepsis as a potential causative factor for indomethacin failure in premature infants with symptomatic patent ductus arteriosus. Lancet i:977
Seyberth HW, Knapp G, Wolf D, Ulmer HE (1983) Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus. Eur J Pediatr 141:71–76
Thalji AA, Carr I, Yeh TF, Raval D, Luken JA, Pildes RS (1980) Pharmakokinetics of intravenously administered indomethacin in premature infants. J Pediatr 97:995–1000
Vert P, Bianchetti G, Marchal F, Monin P, Morselli PL (1980) Effectiveness and pharmacokinetics of indomethacin in premature newborns with patent ductus arteriosus. Eur J Clin Pharmacol 18:83–88
Weninger M, Pollak A, Ganzinger U, Khoss AE, Salzer-Muhar U, Lischka A, Vergesslich KA, Salzer HR (1987) Beeinflussung der Nierenfunktion durch Indomethacin bei beatmeten Frühgeborenen mit hämodynamisch wirksamem Ductus arteriosus Botalli. In: Balzar E, Bulla M, Kleinberger G, Zweymüller E (eds) Akutes Nierenversagen im Kindesalter. Wiener Intensivmedizin Tage 1986, Schattauer, Stuttgart, pp 31–36
Yaffe SJ, Friedman WF, Rogers D, Lang P, Ragni M, Saccar C (1980) The disposition of indomethacin in preterm babies. J Pediatr 97:1001–1006
Yeh TF, Luken J, Raval D, Thalji A, Carr I, Pildes RS (1983) Indomethacin treatment in small versus large premature infants with ductus arteriosus: comparison of plasma indomethacin concentration and clinical response. Br Heart J 50:27–30
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weninger, M., Pollak, A., Salzer-Muhar, U. et al. Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus. Eur J Pediatr 149, 138–140 (1989). https://doi.org/10.1007/BF01995866
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01995866